MRTX News and Press, Mirati Therapeutics Inc. From 11/07/18

SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14 th at 1:40 p.m. MST / 12:40 p.m. ...

Mirati Therapeutics (NASDAQ: MRTX ): Q3 GAAP EPS of -$0.85. More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2018 . "We are pleased that our sitravatinib and MRTX849 (KRAS) programs are ad...

SAN DIEGO , Nov. 5, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two oral presentations at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual Meeting to be held November 9-11, 201...

SAN DIEGO , Oct. 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 tria...

Intellia Therapeutics (NASDAQ: NTLA ) initiated with Neutral rating and $24 (21% upside) price target at Credit Suisse. Shares up  1%  premarket. More news on: Intellia Therapeutics, Inspire Medical Systems, Inc., Kodiak Sciences, Healthcare stocks news, Stocks on the move, , ...

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CSG Systems International, Inc. (NASDAQ:CSGS), Zumiez Inc. (NASDAQ:ZUM...